5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
5-yr-white-trans
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

Numbers Steady after Limited September Outputs from pCPA and CADTH

October 16, 2020
-
Market Access News
-
Posted by MORSE - < 1 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): September 2020 Trends and Insights

 

September 2020 Highlights:

  • 1 product completed CADTH review
  • 0 products initiated pCPA negotiations
  • 2 negotiations were completed with an LOI
  • 0 negotiations were closed without an LOI
  • 1 file was closed without negotiation

 

Files Under pCPA Consideration:

CADTH issued 1 new recommendation in September (25 files as of September 30).

PRODUCT INDICATION SPONSOR HTA REC’N* DATE
Zejula (niraparib) Ovarian Cancer GlaxoSmithKline pCODR 21 Sep

* REC’N DATE = Date of CDEC Final Recommendation (CDR), Date Notification to Implement Issued (pCODR)

 


 

Negotiation Initiation:

The pCPA initiated 0 new negotiations in September (26 active negotiations as of September 30, 2020)

 

Completed/Closed Negotiations:

The pCPA completed 2 negotiations with a Letter of Intent (LOI) in September 2020.

 

PRODUCT INDICATION SPONSOR LOI DATE TTN*
Adcetris

(brentuximab vedotin)

Peripheral T-Cell Lymphoma Seattle Genetics 21 Sep 80
Admelog

(insulin lispro)

Diabetes mellitus, type 1 & 2 Sanofi-aventis 30 Sep 245

* TTN = Time to Negotiate in calendar days

 

Signals Decoded:

 

September saw the first successful negotiation of a Humalog biosimilar while Adcetris completed pCPA negotiations for a third indication.

 

Not Negotiated:

The pCPA declined to negotiate 1 file in September 2020.

 

PRODUCT INDICATION SPONSOR DECLINE DATE TTD*
Tecentriq & Avastin
(atezolizumab & bevacizumab)
Non-Squamous Non-Small Cell Lung Cancer Hoffman-La Roche 1 Sep 43

* TTD = Time to Decline in calendar days

 

 

Signals Decoded:

 

The Tecentriq & Avastin combination for Non-Squamous Non-Small Cell Lung Cancer received a “Do Not List” recommendation from pCODR.

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
pCPA Activity increases in October 2020
NEXT POST →
An Uncharacteristically Slow August Gives Way to an Uncertain Fall

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2022 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
Numbers Steady after Limited September Outputs from pCPA and CADTH